– atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics approvals to initiate a Phase 1 trial to assess the safety and tolerability of orally administered EMP-01 in 32 healthy volunteers – EMP-01 is a 3,4-methylenedioxy-methamphetamine (MDMA) derivative under development for the treatment of post-traumatic…


Previous articlePT359 – Sawyer Hurwitz – Art, Philosophy, Sexuality, and “Psychedelics Tonight”
Next articleBetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives